Group 1 - The People's Bank of China will conduct a 700 billion yuan reverse repurchase operation with a term of 3 months (91 days) [1] - The China Securities Regulatory Commission emphasizes risk prevention, strong regulation, and promoting high-quality development in the capital market [1] - The new version of the basic medical insurance drug catalog and the first version of the commercial insurance innovative drug catalog are expected to be released in December and implemented from January 1, 2026 [2][3] Group 2 - True Love Home announced a potential change in control, leading to a suspension of trading from November 5, with an expected duration of no more than 2 trading days [5] - Shida Group plans to acquire 95% of Fujian Shuchan Ming Shang Technology Co., Ltd. for 185 million yuan, which is expected to enhance its main business revenue and profit scale [5] - Fuyao Glass has completed the registration of a change in its legal representative, with no other changes to its business license [7] Group 3 - The implementation of artificial intelligence in healthcare is set to enhance the quality of health services, with a goal to establish high-quality data sets and intelligent applications by 2027 [4] - The China Securities Regulatory Commission aims to improve the efficiency of overseas listing filings and expand the scope of stock trading through the Shanghai-Hong Kong Stock Connect [2]
【财经早报】7000亿元!央行 今日操作
Zhong Guo Zheng Quan Bao·2025-11-04 23:04